A new report presents post-mortem neuropathological follow-up of patients 4 months to 15 years after they received active amyloid-β (Aβ) immunization during its first trial in Alzheimer disease. The study documents effects on plaque clearance, tau pathology, plasma anti-Aβ antibody titres and final cognitive status; variability was seen between patients.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Alzhemer’s Association. 2019 Alzheimer’s disease facts and figures. Alzheimers Dement. 15, 321–387 (2019).
Selkoe, D. J. & Hardy, J. The amyloid hypothesis of Alzheimer’s disease at 25 years. EMBO Mol. Med. 8, 595–608 (2016).
Drummond, E. & Wisniewski, T. Alzheimer’s disease: experimental models and reality. Acta Neuropathol. 133, 155–175 (2017).
Herline, K., Drummond, E. & Wisniewski, T. Recent advancements toward therapeutic vaccines against Alzheimer’s disease. Expert Rev. Vaccines 17, 707–721 (2018).
Wisniewski, T. & Goni, F. Immunotherapeutic approaches for Alzheimer’s disease. Neuron 85, 1162–1176 (2015).
Nicoll, J. A. R. et al. Persistent neuropathological effects 14 years following amyloid-beta immunization in Alzheimer’s disease. Brain https://doi.org/10.1093/brain/awz142 (2019).
Bayer, A. J. et al. Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD. Neurology 64, 94–101 (2005).
Charidimou, A. et al. Emerging concepts in sporadic cerebral amyloid angiopathy. Brain 140, 1829–1850 (2017).
Maarouf, C. L. et al. The biochemical aftermath of anti-amyloid immunotherapy. Mol. Neurodegener. 5, 39 (2010).
Goni, F. et al. Anti-β-sheet conformation monoclonal antibody reduces tau and Aβ oligomer pathology in an Alzheimer’s disease model. Alzheimers Res. Ther. 10, 10 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Wisniewski, T. Follow-up of active Aβ immunization in Alzheimer disease. Nat Rev Neurol 15, 495–496 (2019). https://doi.org/10.1038/s41582-019-0239-4
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41582-019-0239-4